| Name | Title | Contact Details |
|---|
We are a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases.
NextBio is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Accelerator Life Science Partners catalyzes the development and commercialization of breakthrough biotechnology innovations.
Frontier Medicines is a pre-clinical stage biopharmaceutical company developing breakthrough medicines that redefine the course of debilitating diseases. According to the American Cancer Society, 1,762,000 new cancer cases and 607,000 deaths from cancer are expected to occur in the US in 2019. Our focus is developing treatments against important cancer-causing proteins that the biopharma industry hasn`t found a way to treat (or “drug”) with pharmaceutical interventions. After decades of research, this has become one of the most critical challenges in addressing human disease and advancing oncology therapy --central to the research at Frontier Medicines. Frontier Medicines is using chemoproteomics – an innovative approach to chemically interrogate proteins in living systems – to discover and pharmacologically target new binding pockets (or “hotspots”) on proteins, making them accessible to small-molecule drug discovery and development. The company`s proprietary chemoproteomics platform also integrates advanced computational approaches and machine learning to further accelerate the path to drug discovery.
OncoArendi Therapeutics SA (WSE:OAT) is a Polish innovative biotechnology company specializing in research, development and commercialization of innovative small molecule drugs for treatment of respiratory diseases and cancer.